Cumberland

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

CPIX

Biotech

News

Health Care

Movers

Trading Ideas

General

Cumberland Pharmaceuticals&#39; Phase 2 trial shows ifetroban improves heart function in Duchenne muscular dystrophy patients.

Cumberland Pharmaceuticals&#39; Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Wall Street

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

Eurozone

Intraday Update

Markets

CMRX

CRVO

QURE

YEXT

S&amp;P 500 Edges Lower; AutoZone Posts Downbeat Earnings

Turning to Gold

Commodities

OLLI

Gold Gains Over 1%; Ollie&#39;s Bargain Outlet Shares Jump After Q3 Earnings

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland Pharmaceuticals Inc

Press Releases

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

FDA APPROVES ACETADOTE® sNDA

Stocks to Watch in December 2025: LDTC, CPIX, PNPN.V, ZEO, and More Inside

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

CLLXF

CRDF

KGFMF

LDTC

PNPNF

PRSO

STRRF

TSXV:CNX

TSXV:KFR

TSXV:PNPN

TSXV:VRR

VRRCF

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

Biote

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

China Pharma Holding

Ikena Oncology

Opus Genetics

Iterum Therapeutics

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Veru

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

Ventyx Biosciences

Comments

Cumberland

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell